Higher Motor Activity in Schizophrenia Patients Treated With Olanzapine Versus Risperidone

被引:22
|
作者
Walther, Sebastian [1 ]
Horn, Helge [1 ]
Razavi, Nadja [1 ]
Koschorke, Philipp [1 ]
Wopfner, Alexander [1 ]
Mueller, Thomas J. [1 ]
Strik, Werner [1 ]
机构
[1] Univ Bern, Univ Hosp Psychiat, CH-3000 Bern 60, Switzerland
关键词
actigraphy; treatment effects; quantitative motor activity; ATYPICAL ANTIPSYCHOTICS; HALOPERIDOL; PSYCHOMOTOR; SYMPTOMS; SCALE; QUETIAPINE; MOVEMENTS; EFFICACY; SIGNS;
D O I
10.1097/JCP.0b013e3181d2ef6f
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are indications that atypical antipsychotics differ in the probability of causing motor retardation. Whereas olanzapine seems to exert sedation, risperidone might slow patients because of parkinsonism or increased negative symptoms. Objective data on gross motor activity are not available. We present actigraphic data of 16 schizophrenia patients treated with olanzapine (mean dose, 21.1 mg/d) and 23 with risperidone (mean dose, 4.7 mg/d) to investigate possible differences in their effects on motor activity. Participants wore actigraphs continuously for 24 hours at the nondominant arm. Groups did not differ in age, Positive and Negative Syndrome Scale scores, duration of illness, and number of episodes. Patients treated with olanzapine had higher activity levels than those treated with risperidone (P = 0.024); this effect was robust and also present after covarying for chlorpromazine equivalents and Positive and Negative Syndrome Scale scores. Movement index (proportion of active episodes) and the average duration of immobility, however, failed to show any difference between groups. The results indicate that patients on olanzapine are more active during the day than patients on risperidone. It remains unclear whether this difference is due to subthreshold parkinsonism with risperidone or stronger beneficial effects of olanzapine on psychomotor slowing. Because the average duration of immobility remained unaffected, sedation is not likely to be the cause for the observed differences.
引用
收藏
页码:181 / 184
页数:4
相关论文
共 50 条
  • [41] Analysis of Gene Variants Associated with Iloperidone Response in Patients with Schizophrenia Who are Treated with Risperidone or Olanzapine
    Fijal, Bonnie
    Stauffer, Virginia L.
    Kinon, Bruce J.
    Conley, Robert R.
    Poole-Hoffmann, Vicki
    Witte, Michael M.
    Houston, John P.
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 76S - 76S
  • [42] HEALTH-CARE UTILIZATION COSTS AMONG SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE OR RISPERIDONE IN JAPAN
    Nakahara, N.
    Kobayashi, M.
    Kamae, I
    Inagaki, A.
    VALUE IN HEALTH, 2010, 13 (07) : A554 - A554
  • [43] Switching schizophrenia patients previously stable on chronic conventional antipsychotic therapy to risperidone versus olanzapine
    Wang, XH
    Savage, R
    Borisov, A
    Rosenberg, J
    Woolwine, B
    Peelor, M
    May, R
    Feldman, J
    Miller, AH
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S175 - S175
  • [44] Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia
    Zhao, ZY
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (07) : 1039 - 1048
  • [45] D2 receptor binding of olanzapine versus risperidone in patients with first episode schizophrenia
    Lavalaye, J
    Linszen, DH
    Gersons, BPR
    van Royen, EA
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 224 - 225
  • [46] CHARACTERISTICS OF OUTPATIENTS INITIATED ON OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN JAPAN
    Ye, W.
    Nakahara, N.
    Takahashi, M.
    Ascher-Svanum, H.
    VALUE IN HEALTH, 2010, 13 (07) : A554 - A554
  • [47] Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia
    Edgell, ET
    Andersen, WS
    Johnstone, BM
    Dulisse, B
    Revicki, D
    Breier, A
    Gavart, S
    EUROPEAN PSYCHIATRY, 2000, 15 : 408S - 408S
  • [48] Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: A Markov model
    Vera-Llonch, M
    Delea, TE
    Richardson, E
    Rupnow, M
    Grogg, A
    Oster, G
    VALUE IN HEALTH, 2004, 7 (05) : 569 - 584
  • [49] Olanzapine versus risperidone - A prospective comparison of clinical and economic outcomes in schizophrenia
    Edgell, ET
    Andersen, SW
    Johnstone, BM
    Dulisse, B
    Revicki, D
    Breier, A
    PHARMACOECONOMICS, 2000, 18 (06) : 567 - 579
  • [50] Two year outcomes on risperidone and olanzapine in stable patients with schizophrenia
    Marder, S. R.
    Noordsy, D. L.
    Glynn, S. M.
    O'Keefe, C. D.
    Almeida, M. A.
    Drake, R. E.
    Becker, D. R.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 444 - 445